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CASE

REPORT

Neutrophil-rich, noncollagenous 16A
domain-negative bullous pemphigoid
associated with psoriasis
Morgan E. Sussman, BS, BA,a Shoshana K. Grossman, MD,a Sylvia Hsu, MD,a Jason B. Lee, MD,b and
Kiran Motaparthi, MDc
Philadelphia, Pennsylvania and Gainesville, Florida
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INTRODUCTION
Bullous pemphigoid (BP) is the most common
autoimmune bullous disease.1 The association
between BP and psoriasis has been frequently
reported.2 The most common histopathologic and
serologic findings in patients with BP include a
subepidermal blister with eosinophils3,4 and
BP180-noncollagenous 16A (NC16A) reactivity,
demonstrated using enzyme-linked immunosorbent
assay (ELISA).1 Uncommonly, the histopathology of
BP may be rich in neutrophils. Additionally, epitope
spreading, which leads to the diversification of
autoantigen targeting, has a role in the production
of non-NC16A autoantibodies in patients with BP.5
Herein, we present a case of BP associated with
psoriasis that demonstrated neutrophilic infiltrates
and NC16A domain nonreactivity.

CASE REPORT
A 63-year-old woman with an 8-month history of
untreated, predominantly inverse psoriasis consisting of erythematous, scaly plaques of the inframammary folds, extensor surfaces, and groin presented
with new pruritic blisters on the arms, legs, and trunk
(Figs 1 and 2). Mucosal lesions were absent. Based
on the clinical features and distribution of the
lesions, a clinical diagnosis of coexisting inverse
psoriasis and BP was made. Biopsies were performed for routine histopathology and direct immunofluorescence (DIF).
The histopathology of a plaque obtained from the
inframammary fold was diagnostic for psoriasis
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(Fig 3). The histopathology of a bulla obtained from
the upper portion of the arm demonstrated a
neutrophil-rich subepidermal bulla, for which the
histopathologic differential diagnosis included
bullous systemic lupus erythematosus, linear immunoglobulin (Ig) A bullous dermatosis, dermatitis
herpetiformis, anti-p200 (anti-laminin gamma 1) pemphigoid, and neutrophil-rich forms of BP and epidermolysis bullosa acquisita (Fig 4). The result of DIF
performed on the biopsy material obtained from the
right thigh was initially negative. However, repeat DIF
performed on another sample obtained from the left
thigh demonstrated strong linear deposition of IgG
and C3 at the dermoepidermal junction, consistent
with pemphigoid. Indirect immunofluorescence with
the IgG class using the salt-split skin technique
demonstrated immunofluorescence at the basement
membrane zone in an epidermal pattern. The titer of
antinuclear antibody was only 1:80 in a speckled
pattern, and the patient lacked clinical findings of
systemic lupus erythematosus. Additionally, the result
of ELISA for autoantibodies against type VII collagen
was negative. Taken together with the results of
indirect immunofluorescence, the diagnoses of
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Fig 1. The image shows psoriasis in the patient, with
scaly, erythematous plaque in the suprapubic area.
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Fig 3. The image shows psoriasis histopathology. Left
inframammary fold biopsy: psoriasiform hyperplasia,
parakeratosis, absent granular layer, and intracorneal and
intraepidermal neutrophils (hematoxylin-eosin stain; original magnification: 3100.)

Fig 4. The image shows bullous pemphigoid histopathology. Biopsy of the upper portion of the right arm:
subepidermal blister with neutrophils (hematoxylin-eosin
stain; original magnification: 3100.)

thereafter, the patient’s BP remained under control
during the tapering of prednisone.
Fig 2. The image shows bullous pemphigoid. Tense
bullae can be seen, with surrounding erythema on the
upper portion of the right arm.

epidermolysis bullosa acquisita and bullous systemic
lupus erythematosus were less likely. The results of
initial and repeat ELISAs for circulating autoantibodies
directed against BP180 and BP230 were negative.
Upon initiation of prednisone at 60 mg daily, the
patient experienced rapid clinical improvement in
both psoriasis and BP. Upon tapering of prednisone,
the patient’s psoriasis began to flare. At this time,
adalimumab was added to the treatment regimen;

DISCUSSION
The decision to repeat DIF was driven by the
clinical morphology that was strongly suggestive of
BP in association with psoriasis (psoriasis pemphigoides) and by the risk of a false-negative DIF result
in 33% of biopsies performed on the lower extremity,
although a more recent study demonstrated that the
risk of a false-negative DIF result in patients with BP
does not vary by anatomic site.6 Additionally, a lower
DIF positivity rate in patients with comorbid BP and
psoriasis than in those with BP alone has been
reported.7 Patients with psoriasis alone may have a
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positive DIF result, but this is limited to granular
deposition of C5b-9.4 Thus, the second DIF in this
case, which revealed the linear deposition of IgG and
C3, reflected a true-positive result for BP because this
pattern is not seen in patients with psoriasis alone.4
In this case, the repeat DIF yielded a positive result,
whereas ELISA yielded persistently negative results
for BP180 and BP230 IgG reactivity. DIF is the gold
standard diagnostic test for BP, with a sensitivity of
91%.8 In contrast, the sensitivities of BP180 and
BP230 ELISAs are 89% and 59%, respectively.8,9
The current literature estimates that about 8%-10%
of patients with BP have a negative ELISA result.1
This result, however, represents a false-negative
result due to the limitations of traditional ELISA
testing. Traditional ELISA is used to detect autoantibodies that bind to a specific region of the BP180
structural protein, referred to as the NC16A domain.1
In a study by Fairley et al,1 up to 7.8% of patients with
BP were seronegative for BP180, as determined
using ELISA. Additionally, the authors located 4
extracellular antigenic regions outside of the classic
NC16A domain. Patients with NC16A domainnegative BP cannot be identified using traditional
ELISA.
Epitope spreading is defined as the expansion of
immune response to the same antigen, occurring as a
result of tissue inflammation or physical proximity.5
Epitope spreading occurs within the BP180 protein,
leading to the diversification of immune response.5
Early in NC16A domain-negative BP, autoantibodies
initially target the immunodominant NC16A domain.
Chronic tissuse damage then leads to the exposure
and recognition of secondary epitopes.5 One hypothesis speculates that psoriasis triggers persistent
inflammation at the dermoepidermal junction.2 It is
possible that this chronic inflammation facilitates
epitope spreading in patients with NC16A domainnegative BP.
The association between psoriasis and BP has
been described in several studies,2 and BP is 3.05
times more likely to develop in psoriatic patients
than in matched controls. Notably, psoriasis preceded the development of BP in all patients in a casecontrol study.10 Additional reports of NC16A
domain-negative BP and concurrent psoriasis have
been documented in the literature.1,7 Among a series
of patients with BP and comorbid psoriasis, over 25%
were seronegative for BP180 NC16A, as determined
using ELISA.7
Although BP is traditionally associated with an
eosinophilic infiltrate,3,4 neutrophil-rich BP has been
rarely described.3,11 According to a retrospective
review, neutrophils comprised a significant portion
of inflammatory infiltrates in 16% of patients.12

Neutrophilic predominance has been reported in
cases of drug-induced BP,13 specifically in association with immune checkpoint inhibitor therapy.13 A
recent report described neutrophil-rich BP in association with psoriasis.3 The authors hypothesized
that interleukin 17A, a strong neutrophil chemoattractant that also plays a major role in psoriasis
pathogenesis, induces the formation of neutrophilpredominant blisters.3
Corticosteroid administration in patients with
psoriasis is often avoided because of the potential
risk of flares following steroid withdrawal. However,
flares of psoriasis occur in less than 2% of patients
during or immediately after treatment with systemic
corticosteroids.14 Although the patient presented
here experienced flares following corticosteroid taper, greater evidence supports the use of systemic
steroids in patients with BP and psoriasis.
Methotrexate or interleukin 17 inhibitors, both of
which are effective in both the conditions, can be
used concurrently with or after systemic steroids.15,16
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